Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Repare Therapeutics ( (RPTX) ) has shared an announcement.
On June 17, 2025, Repare Therapeutics held its Annual Meeting of Shareholders, where key decisions were made. Shareholders elected four directors to the board, approved executive compensation on a non-binding basis, and appointed Ernst & Young LLP as the independent registered public accounting firm for 2025.
The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ stock score is primarily impacted by its financial struggles and negative valuation. However, technical indicators show moderate momentum, and recent strategic corporate events provide a positive outlook. The strong cash position offers some buffer against operational inefficiencies.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics Inc. operates in the biotechnology industry, focusing on developing precision oncology medicines. The company is dedicated to advancing innovative therapeutics for cancer treatment.
Average Trading Volume: 284,248
Technical Sentiment Signal: Sell
Current Market Cap: $62.19M
For detailed information about RPTX stock, go to TipRanks’ Stock Analysis page.